Journal
VACCINES
Volume 10, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/vaccines10111794
Keywords
Rift Valley fever virus; RVFV; Rift Valley fever vaccine; RVF
Categories
Funding
- Department of Health Social Care
- Engineering and Physical Sciences Research Council (EPSRC) [EP/R013764/1]
Ask authors/readers for more resources
RVF is a mosquito-borne viral zoonosis that causes harm to both humans and animals. There is a need for more safe and effective DIVA-compatible vaccines due to limitations of the currently available RVF vaccines.
Rift Valley fever (RVF) is a mosquito-borne viral zoonosis that causes high fetal and neonatal mortality in ruminants and a mild to fatal hemorrhagic fever in humans. There are no licensed RVF vaccines for human use while for livestock, commercially available vaccines are all either live attenuated or inactivated and have undesirable characteristics. The live attenuated RVF vaccines are associated with teratogenicity and residual virulence in ruminants while the inactivated ones require multiple immunisations to induce and maintain protective immunity. Additionally, nearly all licensed RVF vaccines lack the differentiating infected from vaccinated animals (DIVA) property making them inappropriate for use in RVF nonendemic countries. To address these limitations, novel DIVA-compatible RVF vaccines with better safety and efficacy than the licensed ones are being developed, aided fundamentally by a better understanding of the molecular biology of the RVF virus and advancements in recombinant DNA technology. For some of these candidate RVF vaccines, sterilizing immunity has been demonstrated in the discovery/feasibility phase with minimal adverse effects. This review highlights the progress made to date in RVF vaccine research and development and discusses the outstanding research gaps.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available